Today, we would like to share a talk given by Stephen Hilbert, President of Oisin Biotechnologies, in which he discusses treating aging and cancer by removing harmful senescent cells.
On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part of the Cooper Union campus in New York City. The packed event saw a range of people from research, investment, and the wider community coming together for a day of science and biotech business presentations and panels.
One of the companies at the event was Oisin Biotechnologies, a company working on therapies that remove harmful senescent cells, which accumulate as we age and drive aging processes through the senescence-associated secretory phenotype (SASP), which leads to chronic inflammation.
Oisin uses a patented technology combining lipid nanoparticle proteins and suicide-gene-containing DNA plasmids to selectively target and trigger apoptosis in senescent cells.
The company is also working on OncoSenX, which is a cancer treatment that uses the same technology but targets a different gene. Oisin anticipates human trials for cancer therapy by 2019, following some very promising mouse results.
We filmed the entire conference and have many more videos of the event coming in the next few months for you to enjoy which you will be added to the NYC video page here. We will also be hosting a second conference in NYC in 2019, as we have decided to make this an annual event.